Moreover, the authors found that enforcing MYC expression in human hepatocellular carcinoma‐derived cells increased the sensitivity to PHA‐767491 [234], a CDK9‐inhibitory tool compound [235]. Here, CDK9 is linked to hepatocellular carcinoma.